The thymus is essential for T cell development and maturation. It is extremely sensitive to atrophy, wherein loss in cellularity of the thymus and/or disruption of the thymic architecture occur. This may lead to lower na€ ıve T cell output and limited TCR diversity. Thymic atrophy is often associated with ageing. What is less appreciated is that proper functioning of the thymus is critical for reduction in morbidity and mortality associated with various clinical conditions including infections and transplantation. Therefore, therapeutic interventions which possess thymopoietic potential and lower thymic atrophy are required. These treatments enhance thymic output, which is a vital factor in generating favourable outcomes in clinical conditions. In this review, experimental studies on thymic atrophy in rodents and clinical cases where the thymus atrophies are discussed. In addition, mechanisms leading to thymic atrophy during ageing as well as during various stress conditions are reviewed. Therapies such as zinc supplementation, IL7 administration, leptin treatment, keratinocyte growth factor administration and sex steroid ablation during thymic atrophy involving experiments in animals and various clinical scenarios are reviewed. Interventions that have been used across different scenarios to reduce the extent of thymic atrophy and enhance its output are discussed. This review aims to speculate on the roles of combination therapies, which by acting additively or synergistically may further alleviate thymic atrophy and boost its function, thereby strengthening cellular T cell responses.
Introduction
The thymus, a primary lymphoid organ, is the site of T cell development and maturation. It is bilobed, situated in the anterior mediastinum at the base of the great vessels and above the heart. Both the lobes of the thymus are enclosed by a capsule, from which trabeculae extend and define thymic lobules. The outer region of the lobule is occupied by the cortex, which is densely packed with immature thymocytes, whereas the medulla, which is present in the inner region of the lobule, contains the more mature cells. The medulla and the cortex are packed by a threedimensional stromal cell network but separated by a vascular corticomedullary junction (CMJ). This framework contributes to the development of immature thymocytes and is composed of mainly epithelial cells, dendritic cells and macrophages. The maturation of thymocytes requires cell-to-cell interactions between thymocytes and thymic epithelial cells (TECs), endothelial cells and mesenchymal fibroblasts. This supporting framework is important for the proper development and maturation of thymocytes. Two types of TECs exist based on their localization in the thymus, cortical thymic epithelial cells (cTECs) and medullary thymic epithelial cells (mTECS), which mediate positive and negative selection, respectively ( Fig. 1 ) [1] .
T cell development
For T cell development to occur, early thymic progenitors (ETPs) from the bone marrow migrate into the thymus via the large venules at the CMJ and are phenotypically identified as CD4 À CD8 À double negative (DN) that lack CD3. During mouse T cell development ( Fig. 2 + SP cells develop from phenotypically distinct DP subsets. At the DP stage, positive selection occurs where more than 90% of the thymocytes fail to develop into CD4 + /CD8 + SP thymocytes. At the SP stage of T cell development, negative selection and maturation of cells occur, after which, na€ ıve CD4 + T helper (T H ) and CD8 + T cytotoxic (T C ) cells egress from the thymus to the periphery as recent thymic emigrants (RTEs) [1] .
T cell development in humans follows a similar pathway as that found in mice with some differences (Fig. 2) . Unlike mice, where four developmental subsets exist in the DN population, there are three subpopulations in the human DN thymocyte subset, based on the expression of CD34, CD38 and CD1a. In addition, the proportion of DN1 cells of mice is greater than its counterpart in humans, that is, the CD34 + CD38 À CD1a À cells [4] . The ISP cells in mice are predominantly CD4 À CD8 + , while in humans they are mainly CD4 + CD8
À . In mice, three distinct DP stages exist, which can be differentiated on the basis of CD5 and CD3 [2] . Also, CD4 and CD8 are co-expressed at this stage. On the other hand in humans, two stages of development exist prior to the expression of CD3. [5] . TCR gene rearrangements occur in a hierarchical manner, and the TCRD gene is the first to rearrange in the DN2-DN4 subsets. Subsequently, TCRG and TCRB undergo rearrangements in the DN4-ISP stage. The TCRA gene is the last one to rearrange which occurs in the DP stage [4, 6] . The analysis of rearrangements in the TCR is useful for the study of thymic productivity. In fact, thymic output is quantified by methods such as measuring signaljoint T cell receptor excision circles (sjTRECs) in peripheral T cells [7] . sjTRECs are products of the DNA recombination process that occurs during T cell development. During successful rearrangement of the TCRA locus, the TCRD gene is deleted and the episomal DNA circles that are generated can be quantified by PCR. These DNA products are stable, are not duplicated during mitosis and Figure 1 The trafficking of thymocytes during development. A healthy thymus is covered by a capsule and divided into distinct lobules by trabeculae. The thymus is broadly divided into two distinct regions, the outer cortex and the inner medulla, which are separated by the CMJ. Progenitor cells from the bone marrow enter the thymus through the vasculatures present in the CMJ. The immature thymocytes viz., CD4
À CD8 À double-negative (DN) and CD4 + CD8 + double-positive (DP) cells are present in the cortex. The DN cells post-sequential development give rise to DP cells, which interact with mainly cTECs. Post-selection and maturation, the DP cells generate CD4 + /CD8 + single-positive (SP) cells which migrate towards the medulla of the thymus, where they interact predominantly with mTECs. Post-negative selection and maturation, SP T cell egresses into the periphery.
are diluted with every cell division. During the first step of TCRB locus rearrangement, Db-Jb reorganization occurs and DbJb TRECs are produced. The sj/b TREC is informative of the rearrangements in the TCR loci and acts as a direct measure of thymic ab T cell generation [8] .
Thymic atrophy
The loss in cellularity of the thymus is termed as thymic atrophy, which is a physiological phenomenon and is well known to occur during ageing [9] . In addition, thymic atrophy occurs during numerous scenarios such as stress [10] , malnutrition [11] , infections [8, 12] and cancer therapy [13, 14] . Thymic atrophy may arise due to apoptosis of thymocytes, deterioration of thymic architecture, loss in influx of ETPs to the thymus or a combination of the above scenarios. These manifestations can occur due to either direct (e.g. HIV infection of thymocytes) or indirect (e.g. increase in stress-induced glucocorticoids) effects on the thymus, as will be elaborated subsequently. Rejuvenation of the thymus or its output, that is, the na€ ıve T cell pool may alleviate the morbidity and mortality during numerous clinical scenarios [15] [16] [17] [18] [19] . Therefore, therapeutic interventions are necessary to reduce the extent of thymic atrophy and, consequently, boost the output of the thymus.
Patients with myasthenia gravis and children undergoing cardiac surgery are the only cohorts which provide thymi for studies on human T cell development and thymic processes such as thymic atrophy. Due to this limitation, the majority of the studies on the thymus are restricted to rodents. In this review, we discuss studies on thymic atrophy performed on animal models and mention the available relevant clinical cases in humans. We provide a holistic view and up-to-date information on the reported or available therapeutic interventions targeted to alleviate thymic atrophy.
Conditions leading to thymic atrophy Ageing
Age-associated thymic atrophy leads to loss in cellularity, mass and organization of the thymus, which results in lowered TCR diversity in the periphery [9] . It is likely that thymic atrophy along with other factors contributes to the development of immunosenescence. Age-associated thymic atrophy occurs in the geriatric population, leading to gradual decline in the ability of the immune system to respond to infections and vaccines. Not surprisingly, the elderly population demonstrates higher occurrences of 6 Studies to Lower Thymic Atrophy infections, autoimmune diseases and neoplasia, which contributes towards~23% of the total global disease burden [20] . Numerous factors have been implicated in studies to be responsible for age-related thymic atrophy (Table 1) . Treatments which have led to increase in thymic size during age-associated thymic atrophy are listed in Table 2 . These attempts at rescuing the thymus size and output indicate that interventions may successfully lower age-associated thymic atrophy.
Infections
The phenomenon of infection-induced thymic atrophy is widely reported, but the underlying mechanisms responsible for the process have not been extensively studied. Several experimental models (Table 1 ) and some human studies where infections with pathogens lead to thymic atrophy are known [12] . A recent study has shown that ISPs are the most sensitive, whereas CD8 + SP T cells are the most resistant thymic subset during infection with Salmonella Typhimurium in mice. Furthermore, this study also identified the role of infection-induced IFNc production in slowing down the maturation of CD4 + and CD8 + SP thymocytes [3] . During HIV infection and in the absence of highly active antiretroviral therapy (HAART), chronic and progressive infection sets in, thereby depleting CD4 + T cells in the periphery and leading to AIDS in patients. HIV-1 infects human thymocytes via the chemokine receptors, CXCR4 (highly expressed on immature thymocytes) and CCR5 (expressed at low levels across all thymocyte subsets) [45] . Significant reduction in thymic output is observed especially in younger patients infected with HIV, as measured by sj/b TREC ratio in PBMCs [8] .
In HIV-positive patients, more abundant thymic tissue is associated with larger proportion of absolute numbers of na€ ıve CD4 + T cells [46] . Conversely, patients on HAART with minimal thymic tissue possess lower number of na€ ıve CD4 + T cells. Also, viral rebound in these patients is higher than those patients possessing greater thymic tissue [47] . Some of the key factors involved in thymic atrophy during infections are listed in Table 1 .
Often infections lead to sepsis, which remains one of the most frequent causes of deaths of patients in intensive care units. Lymphopenia post-surgery and trauma increase the risk of nosocomial sepsis and consequent immunosuppression in patients [48] . Apoptosis of thymocytes and splenocytes demonstrated in mice [49] and lymphocyte depletion in patients [50] during sepsis can alter the Activation of the inflammasome Nlrp3 and caspase-1 in the thymus [22] Loss in expression of the appetite-stimulating hormone, ghrelin and ghrelin receptor
Thymic atrophy and adipocyte infiltration. Supplementation of ghrelin increases the ETPs, reduces adipocyte deposition and rejuvenates the ageing thymus with enhanced numbers of RTE and greater diversity of the TCRs [23] Build-up of intrathymic adipocytes
Reduces thymic cellularity and deterioration of the thymic microenvironment. Calorie restriction reduces lipid-expressing cells in the thymus, aids in maintaining the thymic stromal microenvironment and increases the frequency of na€ ıve T cells in aged mice [24] Thymocyte apoptosis in mice that undergo CLP [35] Ó 2017 The Foundation for the Scandinavian Journal of Immunology adaptive immune response, leading to immunosuppression, which may adversely affect the mortality and morbidity.
The most commonly used animal models for studying sepsis are LPS (also known as endotoxin) administration and caecal ligation and puncture (CLP), which result in endotoxic shock and polymicrobial sepsis, respectively. Homing of bone marrow progenitor cells to the thymus, as measured by reduction in percentage of ETPs, is affected during sepsis induced by CLP, LPS or poly I:C injection in mice. For instance, in mice that undergo CLP, thymic atrophy arises due to severely low frequencies of thymic ETPs which lead to development of T cell lymphopenia and reduced TREC amounts. In addition, the downregulation of lymphoid-associated genes occurs in haematopoietic stem cells and progenitor cells from these mice. Consequently, there are greater numbers of myeloid lineage cells than cells of the T cell lineage [51] . Some of the factors involved during thymic atrophy during sepsis are listed in Table 1 .
Transplantation
Bone marrow transplantation (BMT) is successful in treatment of haematological, oncological, genetic and immunological malignant diseases and extends the survival of patients. Immune reconstitution in patients, especially in the T cell compartment, is inefficient primarily owing to age-associated thymic atrophy which may lead to lifethreatening opportunistic infections [52, 53] . Studies on the recipients of umbilical cord blood transplantation have shown that children, compared to adults, possess higher sjTRECs amounts and greater TCR diversity, na€ ıve T cell numbers and display superior in vitro lymphocyte cell proliferation [52] . Post-allogeneic BMT, complications such as graft versus host disease (GVHD) may arise. During GVHD, mature T cells from the donor react strongly against the histocompatibility antigens of the host. In mice, during GVHD, TECs undergo apoptosis by IFNc secreted from donor T cells in a STAT-1 and caspasedependent manner [54] . Acute GVHD (aGVHD) increases the risks of chronic GVHD, a leading cause of morbidity and mortality in BMT patients. In aGVHD, autoimmunity can manifest due to lower expression of AIRE, a transcription factor responsible for ectopic expression of tissue-restricted peripheral self-antigens by mTECs and regulating negative selection [55] . An important role of the thymus is also observed in middle-and old-aged patients undergoing haematopoietic stem cell transplantation (HSCT) [56] . Long-term immune reconstitution in patients undergone HSCT has been reported to be mainly thymus-dependent [57] . Thymic-driven processes are essential for T cell reconstitution to occur post-transplantation, considering the strong correlation found between low thymopoiesis and high risk of developing opportunistic infections in patients after allogeneic HSCT [53] .
Cancer
The thymus is known to extensively involute during cancer and cancer chemotherapy in mice. A block at the DN stage of T cell development [58] , defect in function of thymic stromal cells (TSC) [59] and downregulation of the antiapoptotic molecules, Bcl-X L and A1, in thymocytes [60] , have been attributed to cause thymic atrophy in tumourbearing mice. In fact, thymic transplantation in conjunction with BMT in tumour-bearing mice [61] and thymic regeneration in leukaemic mice [62] facilitate tumour regression and enhance antileukaemic T cell responses, thus prolonging the lifespan of these mice. In humans, the thymus involutes during cancer chemotherapy but rejuvenates during the recovery phase in patients [13, 14] . In all likelihood, cancer and its therapy lead to atrophy of the 
Therapeutics to reduce thymic atrophy
The above studies underscore the functioning of the thymus in reducing morbidity and mortality associated with a variety of clinical conditions. Thus, strategies to reduce the atrophy of the thymus and, consequently, enhancing its output are essential for immune reconstitution [9] . In the next section, successful strategies to alleviate thymic atrophy and increase its output are discussed in detail.
Nutritional supplementation
Zinc
One of the well-known parameters of malnutrition is thymic atrophy. Not surprisingly, the immune system is known to be impaired during malnutrition, making it a possible risk factor for infectious diseases especially during childhood [11] . Diet deficient in zinc has been reported to contribute towards hypocellularity of the thymus in mice. Elevated corticosterone levels and fewer T cell numbers in the thymus as well as in the spleen are observed in zincdeficient rats [63] . Supplementation of zinc in aged mice leads to lower age-associated thymic atrophy with partial recovery of lymphocyte functions, as measured by mitogen responsiveness and NK cell activity [44] . The thymic hormone, thymulin, is secreted by TECs and possesses hypophysiotropic activity. Thymulin is associated with intrathymic as well as extrathymic differentiation of T cells. Zinc serves as the cofactor for this peptide hormone and is essential for its biological activity. In HIV-infected paediatric patients who progress to AIDS, thymulin is found to be very low or undetectable. In such situations, severe zinc deficiency is also observed in patients at different stages of HIV infection. The supplementation of zinc in the diet of late-stage HIV-infected patients reduces morbidity associated with diarrhoea [19] .
Antioxidants
The progression from HIV to AIDS is associated with increased oxidative stress, attributed to lowered glutathione (GSH) levels. Low GSH levels directly correlate with poor survival of HIV-infected patients. Interestingly, the GSH pro-drug N-acetyl cysteine (NAC) enhances the whole blood and CD4 + T cell GSH levels in HIV-infected patients [64] . Likewise, high-dose combination treatment with NAC and vitamin C in majority of patients of HIV leads to higher CD4 + T cell numbers with enhanced amounts of intracellular GSH along with lower HIV RNA plasma levels [15] . Apart from HIV infection, stress conditions such as in tumour-bearing mice, oral provision of the antioxidant, vitamin E reduces thymic atrophy [65] . Antioxidants such as NAC, vitamin C or vitamin E may have similar effects on the thymus in HIV-infected individuals and other scenarios and clinical studies are required to investigate their efficacy in improving thymic output.
Cytokines and chemokines

IL7
The lymphopoietic cytokine, IL7, is predominantly secreted by non-haematopoietic stromal cells and possesses several functions: activation on the phosphoinositide 3-kinase and the Janus kinase-signal transducer and activator of transcription pathway and downregulation of the cyclin-dependent kinase inhibitor p27 [66] . Although the effect of IL7 on the thymic output in aged mice is disputed [7] , it reduces age-associated increase in apoptosis of CD44 + CD25 + and CD44 À CD25 + DN thymocytes and enhances their survival in vitro and as well as numbers of CD44 À CD25 + DN cells in vivo [67] . Successful thymopoiesis and expansion of T cells in the periphery occur in IL7-treated mice post-BMT. There are numerous factors that might contribute to IL7-mediated thymopoiesis. IL7 is produced by TECs, which support survival and maturation of thymocytes in mice [68] . Also, recombinant human IL7 is successful in reducing sepsisinduced thymocyte depletion in mice that undergo CLP [69] .
Importantly, defects in expression or signaling of the IL7 receptor can cause SCID in humans [70] . In a human thymic organ culture system, the administration of exogenous IL7 increases TREC content in foetal and infant thymus, indicating enhanced abTCR rearrangements [71] . In addition, IL7 enhances survival (at low dose) and proliferation (at higher dose) of human RTEs via the PI3K pathway [72] . In the first human clinical trial for IL7, upregulation of Bcl2, induction of cycling and expansion of peripheral T cells including the na€ ıve T cell compartments with a wider TCR repertoire were observed [40] . IL7 amounts are overproduced during late stages of HIV disease progression, facilitate increase in cell surface CXCR4 expression on CD4 + T cells and also induce switch of HIV-1 tropism from CCR5 to CXCR4 [73] . These factors lead to faster progression of HIV infection, as appearance of CXCR4-specific virions is associated with accelerated disease progression [45] . Therefore, IL7 therapy to boost the output of the thymus during HIV-1 infection may be detrimental and further investigations are required.
A phase 1 clinical trial involving recipients of T celldepleted allogeneic HSCT receiving recombinant human IL7 revealed higher TCR diversity and augmentation of effector memory cells, with no effect on T regulatory cells, Ó 2017 The Foundation for the Scandinavian Journal of Immunology NK cells or B cells. Furthermore, in this study, only one patient developed aGVHD [74] . However, conflicting results are reported in plasma of patients undergoing allogeneic HSCT. IL7 amounts in plasma of these patients negatively correlate with absolute lymphocyte counts, severity of aGVHD and overall survival [75] . For IL7 to be used clinically, elucidation of the discrepancy between promising results obtained in mice models of BMT and human clinical trials to those that show a strong negative correlation in human patients need to be assessed. Further clinical trials with greater sample size and additional variables need to be conducted.
Hormones and growth factors
Glucocorticoid (GC) inhibition
GCs directly mediate apoptosis of thymocytes. Dexamethasone, a synthetic GC analogue, activates phosphatidylinositol-specific phospholipase C via protein kinase C, which results in generation of diacylglycerol. Subsequently, diacylglycerol induces an early ceramide generation by activation of acidic sphingomyelinase, which results in caspase-3 and caspase-8 activation, and apoptosis of mouse thymocytes [76] . Therapies with thymopoeitic potential are known to reduce GCs [31, 77, 78] . GCs are a central mediator of thymocyte depletion during infections in mice (Table 1) , and thus, inhibition of its action by inhibitors or adrenalectomy leads to rescue in thymocyte loss [3, 28, 30] . In mice that undergo CLP, administration of RU-38486, a GC antagonist, also reduces thymocyte death [31] . Moreover, testosterone also manifests thymic atrophy via action of GCs, as observed in castrated mice [77] .
Leptin
In mice and humans, the circulating levels of the adipocyte-secreting hormone, leptin, reduce during starvation. Multiple physiological functions have been associated with leptin, which activates several signaling pathways linked to energy homeostasis, food uptake and immune responses [79] . Leptin inhibits LPS-induced in vitro thymocyte apoptosis by reducing Cytosolic phospholipase A 2 , an enzyme that commences the release of arachidonic acid to give rise to eicosanoids. This modulates inflammation, immune responses and caspase-3 expression via the p38 MAPK signaling pathway [79] . In mice, leptin successfully decreases the extent of thymic atrophy, wherein it promotes proliferation of DN cells and reduces apoptosis of DP thymocytes during endotoxemia-induced thymic atrophy. Additionally, it induces intrathymic IL7 amounts with greater survival of TECs, which expresses receptors for leptin [80] , and reduces pro-inflammatory cytokine levels [78] . It is possible that leptin administration may not be beneficial in reducing thymocyte depletion under all conditions, for example, tumourbearing mice contain higher amounts of thymic leptin [81] .
Growth hormone (GH)
Recombinant human GH treatment in mice post-BMT leads to early but transient increase in B cells and CD8 + and CD4 + T cells in the periphery, without affecting GVHD. However, no apparent increase in sjTREC amounts is observed in spite of increased thymic cellularity in GH-treated mice [82] . Notwithstanding these results, GH treatment in HIV-1-infected patients increases thymic mass and its output, as measured by TREC amounts and numbers of total and na€ ıve CD4 + T cells [18] . The possibility of GH exerting its thymopoietic property via thymulin also exists, as it is known to modulate its secretion in rats [83] .
Keratinocyte growth factor (KGF)
Keratinocyte growth factor is a fibroblast growth factor that regulates epithelial proliferation and differentiation in numerous tissues. In the mouse thymus, progressive expression of KGF is observed in thymocytes during development, with it being absent in DN cells and highest in the most mature SP cells [84] , while the expression of its receptor is restricted to TECs [85] . The thymopoietic property of KGF is widely reported. Under normal physiological conditions, KGF increases ETPs and enhances TEC cell numbers in mice. KGF upregulates IL7 amounts in TECs and is successful in enhancing thymic output and increasing the na€ ıve T cell pool in aged mice [37, 38] . Importantly, after autologous CD34 + peripheral blood progenitor cell transplantation in Rhesus monkeys, KGF reduces atrophy by lowering the depletion of DP thymocytes, preserving the architecture of the thymus and expanding the na€ ıve T cells in lymph nodes [86] .
Keratinocyte growth factor reduces thymocyte depletion post-irradiation, cyclophosphamide (Cy) and dexamethasone treatment in mice. Also, it enhances thymopoiesis in middle-aged recipients of allogeneic BMT post-irradiation [37] . In Rag2 À/À mice, increase in the medullary compartment of the thymus is observed post-treatment with recombinant KGF [84] . Moreover, KGF treatment in mice is also successful in completely inhibiting GVHD-induced thymic atrophy by preserving the thymic architecture [85] . A Th2 profile is observed in the donor mice treated with Palifermin (recombinant human keratinocyte growth factor) [87] . KGF administration leads to induction of the T regulatory cells in BMT recipient mice, a factor responsible for reducing the severity of GVHD [88] . Also, aGVHD depletes the Aire + mTEC high cells in the thymus, which is rescued by peritransplant treatment of KGF in mice, and thus increases the diversity of tissue-restricted peripheral self-antigens transcriptome in mTECs [55] . Although KGF has been found to be beneficial in the aforementioned scenarios, no apparent improvement in thymic output is found upon Palifermin administration to HIV-1-infected patients [89] .
Sex steroid ablation (SSA)
The regeneration of the thymus is widely reported to occur post-surgical or chemical castration in mice and humans. The contribution of sex steroids towards age-associated thymic atrophy is well studied. In the thymus, TECs express the androgen receptor (AR), which is crucial in determining thymic cellularity. The absence of the AR in TECs enhances the cellularity of the thymus and increases the survival of donor-derived thymocytes and splenocytes. Similarly, degradation of the AR in mice, achieved by a chemical compound, ASC-J9 â , leads to higher number of donor-derived bone marrow cells, thymocytes and splenocytes [90] . Both oestrogen and testosterone contribute towards development of severe thymic atrophy. Oestrogen depletes bone marrow Flt3 + Sca-1 + c-Kit + cells (potential thymic progenitor cells) and ETP cells in the thymus [91] . On the other hand, testosterone causes apoptosis of thymocytes via thymus-derived GCs, leading to decreased thymic cellularity [77] . Abrogation of thymopoiesis by testosterone is dependent on inhibition of Delta-like 4, the Notch ligand indispensable for T cell lineage commitment, in cTECs. Higher expression of Delta-like 4 is observed post-SSA by a luteinizing hormone-releasing hormone (LHRH) antagonist in mice [36] . Chemical or surgical castration is successful in inducing thymopoiesis and T cell reconstitution post-BMT in mice. Castration followed by BMT in mice increases the cellularity in the bone marrow, where precursors of B cells is greater. In the thymus, the DN, DP and SP cells along with thymic dendritic cells also increase probably owing to lower amounts of TGFb1 and IL6 in TSC [92] . In addition, increase in common lymphoid progenitors in the bone marrow, thymic DN and DP cells along with donor-derived dendritic cells in surgically castrated HSCT recipient mice is observed.
Importantly, donor-derived lymphocyte reconstitution is observed in these mice with no effect on the severity of GVHD [93] . Treatment with a LHRH agonist without aggravating GVHD rescues the cellularity of the thymus, with increase in number of DP, CD4 + SP and CD8 + SP cells and improved thymic architecture. Increase in donorderived cells and overall cell numbers in the bone marrow and spleen is also observed [94] . Young adult mice surgically castrated before BMT displayed greater thymic regeneration. Importantly, administration of a LHRH agonist in aged male patients treated with localized radiation for prostate cancer led to increase in peripheral CD4 + and CD8 + T cells, with improved TREC contents in most patients [16] . Furthermore, the prior administration of a LHRH agonist to HSCT patients increases the peripheral lymphocyte count, especially na€ ıve CD4 + T cells. Also, higher TREC amounts in CD4 + T cells are observed along with more diverse TCR repertoire and superior T cell responses [17] .
Cancer therapies such as anticancer drugs lead to thymic arophy in humans [13, 14] . Cy depletes Ki67 + mTECs, cTECs and non-TEC stromal cells, leading to thymic atrophy in mice. SSA by castration aids in thymic recovery post-Cy treatment (SSA/Cy) by enhancing recovery of the aforementioned TECs. SSA/Cy also enhances the early increase in KGF, CCL19, CXCL12 and IL6. In the periphery, increase in na€ ıve and memory CD4 + and CD8 + T cell numbers is observed post-SSA/Cy treatment in mice [95] . During Cy-induced thymic atrophy, loss of a thymic, non-haematopoietic fibroblast cell subset, CD45 À fibroblast-specific protein 1 (FSP1) + occurs. In transgenic mice, where expression of FSP1 is lower, severe thymic atrophy with loss of mTECs is observed. Additionally in culture, thymic FSP1
+ fibroblasts compared to FSP1 À cells release more IL6, KGF and FSP1, viz. growth factors important for TEC proliferation [96] .
Conclusion
The phenomenon of thymic atrophy is universally observed, which also includes astronauts, in whom the output of the thymus in diminished post-return from space ND, not determined. '+': Beneficial; 'À': Not beneficial, in decreasing thymic atrophy and/or increasing the na€ ıve/total T cell pool in the periphery. The studies in mice, rats, rhesus monkeys and humans are colour coded.
Ó 2017 The Foundation for the Scandinavian Journal of Immunology flights, probably due to stress-induced cortisol amounts [10] . As a result, the adaptive immune response may diminish due to lower thymic output, which leads to unfavourable outcomes during various clinical conditions. Also, T cell reconstitution during HIV infection or post-BMT might also be impaired. In this review, we have discussed the therapies successful in either alleviating thymic atrophy in mice models or increasing the na€ ıve T cell pool or the TREC amounts in T cells in the periphery in mice or humans. We have stressed on the interventions that have boosted the thymic output across various clinical conditions (Table 3) . We hope this review will help in the development of combination therapies to reduce thymic atrophy. For example, both GCs and IFNc are induced upon S. Typhimurium infection and the combination of a GC receptor antagonist in mice lacking IFNc is more efficient in reducing thymic atrophy [3, 28] . Also, IL7 in conjunction with surgical castration confers additive effects on increasing thymic cellularity post-HSCT in mice, compared to the treatments alone [93] . In BMT recipient mice, pretreatment of KGF along with a LHRH agonist enhances TEC numbers, thymopoiesis and thymic output with improved thymic architecture. Concomitant rise of na€ ıve CD4 + and CD8 + T cells and greater TCR diversity in the periphery is also observed, with superior in vivo antigen-specific CD8 + T cell responses [97] . Transduction of BM-derived mesenchymal stem cells with two reported thymopoietic factors, IL7 and stem cell factor, followed by transplantation in mice post-BMT synergistically induces thymopoiesis and aids in T cell reconstitution [98] . The effectiveness of the mentioned treatments will be better understood upon completion of ongoing clinical trials, such as the efficacy of KGF in promoting thymic reconstitution and preventing newer occurrences of autoimmune diseases in patients of multiple sclerosis who are being treated with alemtuzumab, a monoclonal antibody against CD52 (https://www.clinicaltrialsregister.e u/ctr-search/trial/2011-005606-30/GB). Therefore, development of novel strategies to counter thymic atrophy is imperative, which may be applied in relevant clinical scenarios.
